hb bg 12.jpg

PIPELINE

Hummingbird pursues challenging targets that play a key role in diseases that have not yet been effectively drugged.

We are a clinical stage company with a strong pipeline of first-in-class and best-in-class programs. We focus our internal development efforts on programs we can pursue to clinical proof-of-concept, and seeking partners for other targets.

Program

Target/Class

Indication

Research

Pre-clinical

Phase 1

Partner/Funding

HER3

HMBD-001 

Oncology

(solid tumors)

IND

H1 2021

VISTA

HMBD-002

Oncology

IND
H1 2021

Undisclosed

HMBD-004

Multiple Myeloma

Undisclosed

HMBD-011

Lupus

SARS-COV-2

HMBD-115

COVID-19

Partnered Targets

Undisclosed

Undisclosed